Delpharm

Name

Delpharm

Legal name

DELPHARM INDUSTRIE

Website

http://www.delpharm.com/

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

Keywords

• Contract pharmaceutical manufacturing
• Drug development services
• Sterile manufacturing services
• Pharmaceutical CDMO services
• Regulatory affairs services

Headquarters

HQ city

Issy-les-moulineaux

HQ country

France

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Others

Revenue model

1. CDMO Pharmaceutical Manufacturing Services: Delpharm generates revenue through contract development and manufacturing services for the pharmaceutical industry. As a CDMO, the company develops and manufactures medicines on behalf of pharmaceutical laboratories. Revenue is generated through long-term partnerships with pharmaceutical companies for drug product manufacturing across multiple dosage forms. The company reports approximately €1.1 billion in annual revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Delpharm is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical drug development and manufacturing services for pharmaceutical laboratories. The company develops and produces medicines on behalf of clients across four major dosage form categories: solid oral, semi-solid, non-sterile liquid, and sterile (including pre-filled syringes). It operates 18 production sites and 3 development centers across Europe and North America, with integrated pharmaceutical development, regulatory affairs, and visual inspection/secondary packaging capabilities.

Product overview

Delpharm is a leading Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical manufacturing services. The company operates a multi-site network across Europe and North America with 18 production sites and 3 development centers, generating €1.1 billion in revenue. Delpharm's core offering spans four main pharmaceutical dosage form categories: solid oral forms (tablets, capsules, sachets), semi-solid forms (creams, ointments, suppositories), non-sterile liquids (solutions, syrups, nasal sprays), and sterile forms (pre-filled syringes, injectable solutions). The company also provides integrated pharmaceutical development services and regulatory affairs support. With a capacity exceeding 300 million liquid units annually and over 8,000 product references, Delpharm serves 170 clients across 140 countries, positioning itself among the top 5 internationalCDMOs.

Differentiator

Problem solved

Functional benefit

Brands

• Delpharm Academy: Internal training and development program for Delpharm employees offering in-person and online training courses, with over 170 training sessions organized and 1,500+ employees trained in 2023.

Products and services

• Solid Oral Dosage Forms Manufacturing

Quantifiable outcome

• Over 300 million liquid pharmaceutical units produced per year
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• ACVmed Consortium (Université Bourgogne Europe, École de Biologie Industrielle)coreStrategic or Co-development Partner · 19 May 2026Delpharm Dijon participates in the ACVmed project alongside Université Bourgogne Europe and École de Biologie Industrielle. The project aims to measure and reduce the carbon footprint of pharmaceutical manufacturing processes through a life cycle assessment (LCA) approach. This pilot project, supported by Santenov Dijon Bourgogne and Dijon Métropole, develops analytical methods applied to a concrete industrial case and strengthens teams' competencies in decarbonation. This initiative is part of Delpharm's commitment to the environmental transition of its industrial activities.
• Santenov Dijon BourgogneminorStrategic or Co-development PartnerSupporting partner in the ACVmed decarbonation project at Delpharm Dijon, alongside Dijon Métropole.
• Dijon MétropoleminorStrategic or Co-development PartnerSupporting partner in the ACVmed decarbonation project at Delpharm Dijon.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Recipharm: Swedish-headquartered CDMO with comparable scale (around €1.2B revenue at acquisition) and similar multi-form capabilities across solid, semi-solid, sterile, and biologics. Acquired by EQT in 2021, making it a near-direct comparable for a private CDMO of Delpharm's scale and geography.
• Fareva: French privately-held CDMO with comparable European footprint and multi-form pharmaceutical manufacturing capabilities. As a France-headquartered private competitor with similar customer profile (pharma laboratories), Fareva is one of Delpharm's closest direct competitors in Europe.
• Siegfried Holding: Swiss-listed CDMO (SIX: SFZN) with similar revenue scale (CHF ~1.3B) and capabilities across small-molecule API and drug product manufacturing. A closely comparable publicly-traded peer with comparable dosage form breadth and European footprint.
• Aenova Group: German privately-held CDMO owned by BC Partners with comparable scale (reportedly ~€800M+ revenue) and similar multi-form capabilities including solids, semi-solids, liquids, and sterile. Direct European CDMO competitor.
• Vetter Pharma: German privately-held CDMO specializing in aseptic fill-finish of prefilled syringes, cartridges, and vials. Direct comparable for Delpharm's sterile manufacturing business at Tours, particularly for complex biologics and injectable therapeutics.
• Almac Group: Northern Ireland privately-held CDMO with comparable capabilities in pharmaceutical development, commercial manufacturing, and clinical supply across solid dose and sterile forms. Direct competitor for European pharma development and manufacturing contracts.
• Famar Health Care Services: Greek-headquartered European CDMO with comparable manufacturing services across multiple dosage forms including sterile, semi-solid, and liquid pharmaceutical forms. Direct European competitor for contract manufacturing services.

Broad incumbents

• Catalent (Novo Holdings): U.S.-based large-scale CDMO with much broader biologics and gene therapy capabilities, recently acquired by Novo Holdings for ~$16.5B. Comparable in drug product services but operates at significantly larger scale with deeper biologics exposure than Delpharm.
• Lonza Group: Swiss-listed global CDMO leader (SIX: LONN) with ~CHF 6B+ revenue and leadership position in biologics manufacturing, cell and gene therapy, and small molecules. Overlaps with Delpharm in sterile fill-finish and solid dose but at materially larger scale and biologics depth.
• Thermo Fisher Scientific (Pharma Services): U.S.-listed life sciences giant (NYSE: TMO) with a substantial Pharma Services CDMO segment (formerly Patheon) that competes broadly across the full CDMO value chain. Operates at much larger scale with deeper resources than Delpharm across both small molecule and biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks2 records

Key highlights7 records

Customer concentration

• LinkedInfr.linkedin.com/company/delpharm

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delpharm